Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV vs Subcutaneous Heparin for VTE Prophylaxis in Critically Ill Patients
NCT02707263Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Mar 2016
- Primary completion
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of heparin in venous thromboembolism (VTE) (2 arms), sponsored by NYU Langone Health. Primary endpoint: Comparison of Coagulation (Anti-Xa levels) at 3 days. Planned start Mar 2016; status: withdrawn.
02
Drugs
heparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02707263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02707263.